Diabetes Care:糖尿病是COVID-19住院患者早期不良结局的危险因素

2020-10-01 MedSci原创 MedSci原创

在COVID-19住院患者中,调整肥胖后,糖尿病与患者早期不良结局相关。这些发现有助于为有COVID-19风险的糖尿病患者提供以患者为中心的治疗决策。

2019新型冠状病毒病(COVID-19)住院患者中糖尿病和肥胖症患病率较高,但其对COVID-19患者早期结局的影响知之甚少。近日,糖尿病领域权威杂志Diabetes Care上发表了一篇研究文章,研究人员旨在检验以下假设:在住院治疗的COVID-19患者中,校正肥胖症后,糖尿病是COVID-19患者早期不良结局的危险因素。

研究人员使用的数据来自于麻省总医院(MGH) 2020年3月11日至2020年4月30日住院COVID-19患者的登记数据。该研究的主要结局为入住重症监护病房(ICU)、需要机械通气以及在就诊后14天内死亡。根据人口统计学特征、肥胖和相关合并症调整Logistic回归模型。

在450例患者中,178例(39.6%)患者有糖尿病,主要是2型糖尿病。糖尿病患者与非糖尿病患者相比,入住ICU(分别为42.1% vs. 29.8%,P=0.007)、需要机械通气(37.1% vs. 23.2%,P=0.001)和死亡(15.9% vs. 7.9%,P=0.009)的比例更高。在多变量logistic回归模型中,糖尿病与更高的入住ICU(比值比为1.59 [95%CI为1.01-2.52])、机械通气(1.97 [1.21-3.20])和14天死亡(2.02 [1.01-4.03])的几率相关。肥胖与入住ICU(2.16 [1.20–3.88])和机械通气(2.13 [1.14–4.00])更高几率相关,但与死亡无关。

由此可见,在COVID-19住院患者中,调整肥胖后,糖尿病与患者早期不良结局相关。这些发现有助于为有COVID-19风险的糖尿病患者提供以患者为中心的治疗决策。
 
原始出处:
 
Jacqueline Seiglie,et al.Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19.Diabetes care.2020.https://care.diabetesjournals.org/content/early/2020/09/29/dc20-1506

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 1240394fm61暂无昵称

    收了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1902496, encodeId=5647190249687, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue May 25 23:37:38 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761516, encodeId=3e7e1e61516d3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Apr 18 11:37:38 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639616, encodeId=0e31163961692, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Feb 19 08:37:38 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889768, encodeId=6b9f889e684f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Oct 02 23:11:39 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889642, encodeId=3aa3889642b3, content=收了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Fri Oct 02 06:22:04 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043347, encodeId=ba10104334e89, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Oct 02 01:37:38 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

PUDF2020丨张俊清教授:从ADA新指南看Ⅱ型糖尿病综合优化管理

糖尿病是一种慢性疾病,糖尿病的治疗和管理需要以疾病结局为导向调整治疗策略并需要长期坚持,如果不能长期有效的来进行管理,可能会对患者带来不利的影响。

J Appl Oral Sci:牙周治疗可改善牙周炎和糖尿病患者的全身炎症状况

目前关于牙周治疗对2型糖尿病(T2D)和牙周炎患者的血糖控制和全身炎症的影响尚无定论。本研究旨在评估洁治和根面平整(SRP)对2型糖尿病(T2D)患者的代谢控制和全身炎症的影响,研究结果已在线发表于J

Diabetes Care:1型糖尿病患者运动后血糖控制与残余β细胞功能有关

本研究旨在探究1型糖尿病(T1D)患者急性运动后,残余β细胞功能对连续血糖监测(CGM)结果的影响,研究结果已在线发表于Diabetes Care。

BMJ:SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险

与DPP-4抑制剂相比,糖尿病患者接受SGLT2抑制剂后,心血管事件风险可进一步降低

Diabetes Care:CGM衍生指标、A1C与1型糖尿病老年患者低血糖风险的关系

连续血糖监测(CGM)目前普遍应用于1型糖尿病(T1D)的管理。CGM衍生的变异系数(CV)测量血糖变异性,血糖管理指标(GMI)测量平均血糖(以前称为估计A1C)。然而,它们与实验室测量的A1C和T